Enlivex Ltd. (ENLV)
| Market Cap | 1.48M -94.0% |
| Revenue (ttm) | n/a |
| Net Income | 3.19B |
| EPS | 4,469.19 |
| Shares Out | 1.24M |
| PE Ratio | 0.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,266 |
| Open | 1.300 |
| Previous Close | 1.245 |
| Day's Range | 1.180 - 1.312 |
| 52-Week Range | 1.180 - 434.400 |
| Beta | 1.61 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About ENLV
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was forme... [Read more]
Financial Performance
Financial StatementsNews
Enlivex reports favorable 12-month Allocetra knee osteoarthritis trial data
Enlivex announced favorable 12-month topline data from the Phase IIa stage of its Phase I/IIa trial evaluating Allocetra in patients with moderate to severe knee osteoarthritis. In patients aged 64…
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
In patients aged 64+: 79.2% of patients achieved a clinically meaningful response (reduced pain and improved knee function) in the Allocetra™ group vs. 47.6% in the placebo group at 12 months (p=0.027...
Enlivex Therapeutics randomizes patients in Allocetra trial
Enlivex announced that 135 patients, out of a total planned 182, have been randomized and were administered the first injection of Allocetra in the company’s Phase 2b clinical trial of…
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
• 135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and i...
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced rec...
Enlivex Therapeutics trading halted, news pending
19:50 EDT Enlivex Therapeutics (ENLV) trading halted, news pending
Enlivex Therapeutics implements 1-for-16 reverse share split
Enlivex announced a 1-for-16 reverse split of its ordinary shares, which will become effective on October 27, on which date the company’s ordinary shares will trade on Nasdaq on a…
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1...
Enlivex Therapeutics to reduce workforce by 60%
Enlivex announced a cost reduction plan, effective immediately, designed to substantially reduce the company’s cash burn and focus its resources on the execution of its Phase 2b clinical trial of…
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Nes-Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a ...
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd.
Enlivex Therapeutics registers to sell 10M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10M ordinary shares. The company is not selling any shares under…
Enlivex Registration statement: Registration filing
Enlivex filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Enlivex Therapeutics target adjusted to $80 from $20 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Enlivex Therapeutics (ENLV) to $80 from $20 and keeps a Buy rating on the shares. The firm cites the 1-for-15 reverse split…
Enlivex Transcript: Study update
A premium-priced transaction with the Rain Foundation aims to strengthen future financing and leverage treasury assets, while Rain protocol milestones show rapid trading growth and ambitious projections. Allocetra's phase I/IIa results in osteoarthritis are promising, with an ongoing phase IIb study and RMAT designation supporting accelerated development.
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE)...
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including i...
Enlivex Therapeutics announces $400M private placement
Enlivex announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400M of ordinary shares at a price…
Enlivex Announces $400,000,000 Private Placement
Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that...
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up...
Enlivex Therapeutics receives RMAT designation for Allocetra from FDA
Enlivex announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to Allocetra, the company’s clinical-stage immunotherapy, for the treatment of age-related sympt...
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (...
Enlivex Therapeutics trading halted, news pending
19:50 EDT Enlivex Therapeutics (ENLV) trading halted, news pending
Enlivex Therapeutics announces 1-for-15 reverse split
Enlivex announced a 1-for-15 reverse split of its ordinary shares. Beginning on July 9, the company’s ordinary shares will trade on Nasdaq Capital Market on a split-adjusted basis. Published first…
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split...